IN THIS ISSUE

Ed Silverman
Biosimilar companies want the six-month waiting period on sales to start as soon as they file their application, not when the FDA approves the product. The Supreme Court is hearing their case.
Viewpoint
Barbara Antuna, MD

Barbara Antuna, MD

Why patient-friendly communication strategies are more important than ever.
Howard Wolinsky

Eileen Wood
CDPHP

Drugmakers and beneficiaries love coupons and patient-assistance programs, but they give PBMs and health plans a headache.
Legislation & Regulation
Richard Mark Kirkner

Diana Furchtgott-Roth
Manhattan Institute

Diana Furchtgott-Roth, adviser to three Republican presidents, gives her take on the dismantling of the ACA and what may come after.
Jan Greene
Health reimbursement arrangements are back and could mean health coverage for employees of small businesses. Skeptics believe few businesses will offer HRAs.
Viewpoint
Zachary Hafner

Zachary Hafner
Advisory Board

Payers and providers need to collaborate to manage costs. Encouraging use of generics and biosimilars is one way they can slow down the soaring drug spend.
Tomorrow’s Medicine
Thomas Morrow, MD
That’s the danger when new medications are compared against placebo rather than against over-the-counter products with a history of effectiveness.
Medical Directors Forum
Eneida O. Roldan, MD, MPH, MBA

Eneida O. Roldan, MD

News & Commentary
Frank Diamond